Dalfampridine (4-Aminopyridine) Ein oral verfügbarer Kaliumkanalblocker, der die Gehfähigkeit sowie Muskelkraft und Ausdauer von MS-Patienten verbessern soll. Chemisch ist der Stoff den Aminopyridinen zuzuordnen und wird üblicherweise in 2,5 mg, 5 mg oder 10 mg verschrieben. 4- Aminopyridin wurde 2010 unter dem US-amerikanischen Freinamen Dalfampridine® zur unterstützenden Behandlung der MS, in der EU und in der Schweiz bislang allerdings noch nicht zugelassen. 4-Aminopyridinen wird jedoch vielfach nach Verschreibung durch einen Arzt in Apotheken zu Rezepturarzneimitteln verarbeitet. Sie brauchen also einen Arzt, der es verschreibt und eine Apotheke, die es zubereitet (in Wien z.B. die Allerheiligen-Apotheke). 3. 7. 2012; PubMed.gov; Dalfampridine: A Medication to Improve Walking in Patients with Multiple Sclerosis (July/August). http://www.ncbi.nlm.nih.gov/pubmed/22764324 „CONCLUSIONS: In clinical trials, dalfampridine improved walking speed in approximately one third of patients with MS. The risk of seizures appears to be dose-related and the incidence is low at doses of 10 mg twice daily. Because of the cost, dalfampridine should be reserved for patients who meet criteria for the drug and continued only if they have an adequate response.“ 1. 11. 2012; PubMed.gov; Clinical Overview of Dalfampridine: An Agent With a Novel Mechanism of Action to Help With Gait Disturbances. http://www.ncbi.nlm.nih.gov/pubmed/23123001 „CONCLUSIONS: Dalfampridine has a unique mechanism of action, leading to its approval as the first symptomatic therapy for MS to improve walking speed. The increased risk of seizures can be a significant safety concern and will require health care providers to be diligent in monitoring patients and to ensure adequate patient education. The addition of dalfampridine as symptomatic therapy for MS may lead to additional novel products in the future.“ May 2014; msj¸Dalfampridine improves walking speed, walking endurance, and community participation in veterans with multiple sclerosis: a longitudinal cohort study http://msj.sagepub.com/content/20/6/733.abstract " Conclusions: Dalfampridine-ER (extended release) was associated with short-term improvements in walking speed and community participation, and sustained improvements in walking endurance and self-perceived impact of MS on walking for one year. Our study supports the utility of this medication in late MS." „Bürofick bringt Unglick“ Zur Medikamenten-Übersicht